Big pharma is heading to Barcelona and here's why www.bloomberg.com/news/newslet...

Nobel Prizes by country and year. The dominance of Germany is striking every time. Before 1933, that is. And the utter dominance of America (and the UK) after 1945.

"In a minefield of glitchy AI search and social media, Wikipedia becomes one of the most reliable places on the internet" Read more, via CNN Business ➡️ edition.cnn.com/2025/01/14/b...

Nobody's talking about the fact that some anonymous hero included Jeffrey Goldberg in that Signal group chat. Lighting the way

GSK allegedly just tipped the feds that Pfizer intentionally delayed releasing its Covid vaccine Phase 3 data until after the 2020 election. A very risky move by GSK that could seriously backfire, regardless of whether the accusation is true www.wsj.com/health/pharm...

🎙️Podcast 1957 - La URSS lanza el satélite Sputnik y desata la carrera espacial con Estados Unidos 2025 - DeepSeek revela la competitividad de China en inteligencia artificial Momento DeepSeek: En este episodio analizamos el auge de China en clave biotech open.spotify.com/episode/63Vj...

A dark read from a biotech investor. Some important themes here about prioritizing shareholders substack.com/inbox/post/1...

"We were badly misled about Covid". TLDR, it's about a potential lab origin. Some serious soul-searching to be done on this topic by the scientific community www.nytimes.com/2025/03/16/o...

Roche pays $1.65B upfront to co-develop Zealand Pharma's long-acting amylin agonist for obesity. The deal includes a total consideration of $5.3B and the two companies will split profits evenly in Europe and the US Danish biotech has been on fire lately $ZEAL www.globenewswire.com/news-release...

Now there's talk of a recession and the stock market is crashing. Does anyone still question that the Democrats' problem with the economy is one of communication?

You are not rewriting the genetic code, John Evans, you are rewriting the genetic sequence. The genetic code has been the same since life can call itself life $BEAM

$MLYS announces positive topline data from two pivotal trials in uncontrolled or resistant hypertension. The primary endpoint was met in both #portfolio ir.mineralystx.com/news-events/...

$BEAM positive Ph1/2 data in Alpha-1 Antitrypsin Deficiency, the paradigmatic indication for a base editing approach given that neither a KO nor gene therapy would be sufficient They also priced a $500M offering behind closed doors, this will be controversial www.globenewswire.com/news-release...

Are the longevity crowd barking up the wrong tree because they have mistaken the chicken for the egg? Evidence that epigenetic 'clocks' are driven by somatic mutations www.nature.com/articles/s43... #biosky

The Monsanto acquisition probably ranks as the worst ever by a pharma company Bayer as a whole is now worth less than what it paid for Monsanto, and litigation is putting the company in financial distress. All karma for not having bought small biotech instead :) endpts.com/bayer-eyes-c...

Please no www.marketwatch.com/story/nasdaq...

CytomX/Amgen discontinue masked EGFR T Cell Engager It seems intuitively hard to get to therapeutic exposures if both sides of the bispecific antibody are masked. More encouraging data with Janux' PSMA bispecific where only CD3 arm is masked $CTMX $AMGN $JANX $VIR ir.cytomx.com/news-release...

Giving GPT 4.5 a try and the reasoning capacity is getting scary. Where did the people who said that LLMs were just statistical parrots go?

Dry powder for European biotech: Sofinnova Partners raises €1.2B to fuel the next wave of life sciences innovation sofinnovapartners.com/news/sofinno...

"Coalition of the willing" is the new way Europe needs to operate on everything, not just geopolitics. Just get together the countries who agree on something, and get it done www.theguardian.com/world/2025/m...

Are European labs seeing an uptick in high-quality postdoc applications? Just curious

Stem cell therapy in epilepsy: an interview with Jonathon Parker, investigator in Neurona Therapeutic’s pioneering trial #portfolio www.neurologylive.com/view/stem-ce...

Are low-resolution images in a corporate deck a red flag? yes/no

John Stewart slices his hand while talking drug pricing The biopharma sector needs to fight the common misconception that drug development is funded by taxpayer money. Basic research and development are both equally necessary, but they're very different things www.dailykos.com/stories/2025...

First RIPTAC dosed in humans! #RIPTACs #prostatecancer haldatx.com/halda-therap...

#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy. 🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment 📢 Read more: https://buff.ly/3Dh9kfv #VC

An overwhelming majority are listed in the US. The time is right for Europe to move towards a common listing

This is certainly not the first time big pharma finds fraudulent data after they acquire a drug from a biotech company. But it may be one of the first times where they openly admit it Novo Nordisk alleges fraud after $1.3B deal to buy drug from KBP Biosciences www.reuters.com/business/hea...

Why I Am taking My HAE Cure Idea to My Grave: rnaitherapeutics.blogspot.com/2025/02/why-... $NTLA $BCRX #HAE $KALV $PHVS I may have to change to a different platform, blogger/blogspot is becoming shockingly outdated.

$AZN key 2025 catalysts. AVANZAR trial (Dato-Dxd + durvalumab + chemo) in first-line lung cancer one to watch The combo of ADC + checkpoint inhibitor worked remarkably well in bladder cancer, will this become a broader concept in oncology treatment?

🎙️Nueva entrega de nuestro #Podcast! PÍLDORAS DE BIOTECH💊 🎯 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 📈 Descubre los acuerdos, #tendencias y #retos que marcarán el 2025 en #pharma y #biotech. ▶️ https://buff.ly/3Q5lgnn #YsiosPodcast #BiotechPillsWithJordi

$NVS cardiovascular franchise showing its muscle: Both Entresto and Leqvio were characterized as very poor launches, now they are both major growth drivers www.novartis.com/sites/novart...

#entrevista I🔬#TelescopeBiotechFund , una apuesta estratégica por la #biotecnología cotizada. Descúbrelo con @jordixiol.bsky.social , Partner en @ysioscapital.bsky.social y Horacio Encabo de Andbank en @capitalradiob.bsky.social ▶️ https://buff.ly/3CkLQG7 #FondosDeInversión #MercadoFinanciero

When Warp Drive Bio first launched I remember thinking those people were insane. Never going to work. Now I’m blown away by every piece of new data with $RVMD’s tri-complex inhibitors. The zeal of the convert

Efficacy of pan-RAS and KRAS G12D inhibitors from $RVMD in 2L PDAC: 36% and 30% ORR for daraxonrasib and zoldonrasib, respectively #ASCOGI

Good amycretin data. It looks like it will be able to break the 25% weight loss psychological barrier. The one cagrisema missed and sent Novo down 30%

One more ADC deal with China: Arrivent licenses ADC from Lepu Biopharma for the treatment of colorectal, pancreatic and other GI cancers. Target undisclosed, $47M in near-term payments $AVBP ir.arrivent.com/news-release...

Scientist at a not-to-be-named Nasdaq cell therapy company: "I don't know if we're stupid or visionary"

De novo protein design is the low-hanging fruit of AI for drug discovery www.nature.com/articles/s41...

$RLAY is going after the same target than Scorpion and has treated many more patients Why is $RLAY trading under cash while Scorpion is getting acquired for up to $2.5B? The value of showing single-agent activity in oncology

$GILD paying $250M upfront for LEO Pharma’s preclinical STAT6 portfolio. Talk about a hot target #JPM25 www.businesswire.com/news/home/20...

100 years of quantum mechanics. It remains the most fundamental model for how the universe works, but it still cannot explain gravity, space and time www.nature.com/articles/d41...

The world’s 280 million electric bikes and mopeds are cutting demand for oil 4x more than electric cars due to their staggering uptake in China and elsewhere.

One of my contacts has a theory on why the JPM meeting in San Fran is so conducive to deal making: Jetlag + cocktails.

Amivantamab + lazertinib showed survival benefit over osimertinib in 1L NSCLC with classical EGFR mutations www.targetedonc.com/view/amivant... Meanwhile sunvozertinib, an amivantamab contender in exon20 EGFR-mutated NSCLC, was granted priority review by the FDA www.onclive.com/view/sunvoze...

X is being used as a political weapon against a democratically elected government in the UK. You all really need to stop posting over there

Some me-toos and some long shots, but two stand out: - $NVS $IONS Pelacarsen cardiovascular outcomes trial. Lp(a) has been associated with CV disease since the 1970s. First of a highly anticipated class of medicines - MORF-057 Ph2b in UC. Is $LLY on a roll also in BD and can orals replace biologics

A pretty good year for drug approvals in 2024 www.nature.com/articles/d41... but neurology lags behind recent trends for the year. Top of the list on what to look forward to in 2025 is Suzetrigine (VX-548) for acute (post surgical) pain in Jan!

What a way to start 2025! Our spliceosome blueprint has been recognized by @forbes.com as one of the “Top Five Breakthroughs of 2024”. Huge thanks to my colleagues and my mentor Juan Valcarcel at @crg.eu #Biotech #Spliceosome #RNA #Innovation www.forbes.com/sites/alexkn...

The founder of Christianity, a distinct religion from Judaism centered around the divinity of Jesus, was Paul the Apostle, not Jesus himself. Hyam Maccoby is the author that best encapsulates this notion